

CTT Pharma announces Australia patent approval

24 March 2022 | News

This granted patent is ideal for various medical APIs, including cannabinoids, psychedelics, nicotine, etc., for the market in Australia.



CTT Pharmaceutical Holdings has expanded its reach into additional international markets with a successful patent application of its Oral Strip drug delivery system in Australia. This patent covers "Oral Strip" delivery system, which utilizes micelles to deliver accurate and reliable active ingredient dosages rapidly. The application of micelles in drug delivery is a powerful alternative for dissolving hydrophobic drugs in aqueous environments, minimizing drug degradation and loss, preventing harmful side effects, and increasing drug bioavailability.

This granted patent is ideal for various medical APIs, including cannabinoids, psychedelics, nicotine, etc., for the market in Australia. By increasing geographic footprint, CTT Pharma continues to pursue its new strategy of monetizing its IP through partnerships for its drug delivery technology in many of the world's most rapidly growing markets.

"With Australia legalizing Medical Marijuana, this presents an opportunity, as we are actively looking for partners to offer a smoke-free alternative for patients in Australia," said Ryan Khouri, CEO of CTT Pharma.

CTT is a drug delivery technology company that successfully received Health Canada approval, after which it brought its first product to market as cannabinoid-infused "Dissolve Strips".